Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.

@article{Ma2009ProteasomeEA,
  title={Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.},
  author={Wanlong Ma and Hagop M Kantarjian and Benjamin Nebiyou Bekele and Amber C. Donahue and Xiaoying Zhang and Zhong J Zhang and Susan M O'Brien and Elihu Estey and Zeev Estrov and Jorge E. Cortes and Michael J Keating and Francis J Giles and Maher Albitar},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2009},
  volume={15 11},
  pages={3820-6}
}
PURPOSE Cytogenetic abnormalities are currently the most important predictors of response and clinical outcome for patients with acute myeloid leukemia (AML) or advanced-stage myelodysplastic syndrome (MDS). Because clinical outcomes vary markedly within cytogenetic subgroups, additional biological markers are needed for risk stratification. EXPERIMENTAL DESIGN We assessed the utility of measuring pretreatment proteasome chymotrypsin-like, caspase-like, and trypsin-like activities in plasma… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Similar Papers

Loading similar papers…